Navigation Links
HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market
Date:3/20/2009

SHENZEN, China, March 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that the first batch of Influenca Vaccine (MEVAC-FLU) entered Chilean market. The company will also attend the tender of 2.5 million doses of influenza vaccine for Chile in 2009.

Terry Yuan CEO of HTDS said, "After two years of hard work, we have finished the registration of the influenza vaccine in Chile. The ISP (Instituto De Salud Publica de Chile) issued the GMP certificate to our plant after a strict inspection in June, 2008. In Dec. 2008, we obtained the registration certificate successfully. Now, in Feb.2009, we have exported the first lot of 25,000 units of influenza vaccine (Brand name: Mevac Flu) to Chile. This is the first time for Chinese influenza vaccine to enter the Chilean market. We see this as a good opportunity to open up the South American market for us as a company.

"The Chilean government has a tender project each year for influenza vaccine of 1.5-2.7 million doses. This is a free vaccination for the elder people. In Sep. 2009, Mellow Hope will participate to bid the tender of 2.5 million doses. Since the first lot is being used by the local people, once the vaccine is well-approved, it will be helpful for Mellow Hope to bid the tender."

The company will provide further details as they become available.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pelosi Statement on Reintroduction of the Early Treatment for HIV Act
2. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
3. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
4. Maggots as Good as Gel in Leg Ulcer Treatments
5. New Parkinsons Treatment Shows Promise in Animals
6. Less is more when it comes to treating high blood pressure
7. Scientists trial device to treat chemotherapy-related nausea
8. Khloe Kardashian Receives Body Contouring VelaShape(TM) Treatment Before Photo Shoot
9. Free Community Seminar to Review Treatment Options for Enlarged Prostate
10. Japan Treats First Extracranial Patients Using CyberKnife Radiosurgery
11. New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... campaign returns for a third time to shed lights on the variety of topics ... and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed at ... stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight to ... industry leaders such as Bioness. , As patients feel increasingly concerned about ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... interest stories, courtesy of leaders in the nursing and health care industry. It ... leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... the necessity of health literacy within the technology advancement of diagnostic imaging. According to a ... majority of oncology patients undergo imaging screenings without understanding the nuanced risks associated with ... ... ... Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... , May 26, 2016 ... market growth is the emergence of new treatments. Cardax, ... therapies for osteoarthritis treatment. The therapy is expected to ... Arthritis Research UK is conducting studies to develop new ... study, where the genes involved in osteoarthritis are being ...
Breaking Medicine Technology: